NCT00554151已完成不适用
Mitral Adjustable Annuloplasty Ring Feasibility and Safety Study (MAARS) for Treatment of Patients With Mitral Valve Regurgitation in Open Surgical Repair
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 7
- 主要终点
- Safety: Freedom from major adverse events (MAE)at 30 days. Performance: Technical success rate of implantation of the investigation device.
研究概览
简要总结
Evaluation of the technical feasibility and safety of the Mitral Adjustable Annuloplasty Ring.
详细描述
Establish the technical feasibility and safety of implantation of the investigation device, adjustment of the investigational device post-implantation, and the ability of the investigational device to reduce mitral valve regurgitation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females aged greater or equal to 18 to less than or equal to age
- •Patients with indications to undergo mitral valve repair consistent with ACC/AHA recommendations; including greater or equal to 2+ regurgitation by pre-operative TEE or TTE assessment.
- •Candidate for cardiopulmonary bypass.
- •A Left Ventricular Ejection Fraction greater or equal to 40%.
- •Able and willing to comply with all study requirements, including the required study follow-up visits.
- •Able and willing to five consent and follow study instructions.
- •Female patients of childbearing potential (not surgically sterilized or more than one year postmenopausal), with a negative pregnancy test (serum beta-hCG) within 24 hours prior to mitral valve surgery.
排除标准
- •Any previous cardiac surgery.
- •Any interventional cardiology procedure within six months prior to study to include all patients that have had a drug eluting stent (DES) implanted within 6 months.
- •Evidence of an acute Myocardial Infarction (MI) within 7 days of the intended treatment with the investigational device.
- •Prior mitral valve surgery or valvuloplasty or currently implanted prosthetic valve.
- •Restricted mobility of the mitral apparatus that results in a valvular area less than 3.0 cm
- •Recent or evolving bacterial endocarditis or patients under current antibiotic therapy.
- •Patients with ICD's.
- •Any angiographic or clinical evidence that the investigator feels would place the patient at increased risk with the placement of the device or concurrent medical condition with a life expectancy of less than 12 months.
- •Patients who are immunocompromised or with autoimmune diseases.
- •Patients suffering from renal insufficiency (Creatinine >2.5 mg/dL) or patients with chronic renal failure undergoing dialysis.
- •Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g. sever chronic obstructive pulmonary disease, hepatic failure, immunosuppressive abnormalities, haematological abnormalities).
- •Significant mitral annular calcification.
- •Use of Coumadin, IIbIIIa inhibitors, Clopidigrel (Plavix) or other anti-coagulants within (5) five days prior to surgery.
- •Participation in any study involving an investigational drug or device within the past month, or ongoing participation in a study with an investigational device.
- •Intolerance or hypersensitivity to anaesthetics.
- •Patients in whom transesophageal echo/Doppler is contraindicated.
- •History of bleeding diathesis or coagulopathy.
- •History of stroke within the prior 6 months
- •Subjects to undergo concomitant cardiac repair or replacement other than CABG (less than or equal to 3 vessels) mitral annuloplasty, tricuspid valve repair and ablation therapy for correction of atrial fibrillation. Excluded concomitant procedures are: aortic valve replacement, LV remodeling, surgery and congenital repair.
- •Patients with Euroscore > 10.
结局指标
主要结局
Safety: Freedom from major adverse events (MAE)at 30 days. Performance: Technical success rate of implantation of the investigation device.
时间窗: 30 days, 90 days, 6 months and 1 year
次要结局
- Ability to adjust the investigational device post-ring implantation after the patient has been weaned from CPB. MR reduction to <2+ post procedure, at post operative hospital discharge, at 30 days, at 6 months and one year.(30 days, 90 days, 6 months and 1 year)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
不适用
Mitral Adjustable Annuloplasty Ring Feasibility and Safety StudyMRNL-OMON31130MitralSolutions, Inc.20
Unknown
不适用
Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve RegurgitationMitral Valve RegurgitationNCT01740583Mitralign, Inc.50
进行中（未招募）
不适用
A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral RegurgitationMitral Regurgitation FunctionalMitral Valve DiseaseCardiovascular DiseasesNCT04147884Boston Scientific Corporation4
已完成
不适用
Is Mitral Annuloplasty an Effective Treatment for Severe Atrial Functional MR?Mitral RegurgitationNCT05836376Michele De Bonis55
招募中
不适用
Retrospective observation of mitral valve repair in adultsKCT0006408Koera University Guro Hospital23